Lesser effects of SGLT2 inhibition on intermediate markers of cardiovascular risk, such as glycosylated hemoglobin and body weight, are established among patients with reduced eGFR21 and could reduce the magnitude of cardiovascular protection afforded
Lesser effects of SGLT2 inhibition on intermediate markers of cardiovascular risk, such as glycosylated hemoglobin and body weight, are established among patients with reduced eGFR21 and could reduce the magnitude of cardiovascular protection afforded. rate 60?mL/min per 1.73?m2) and without (estimated glomerular filtration rate 60?mL/min per 1.73?m2) reduced kidney function at baseline, for each included…
Read more